chufangao/CTO huggingface dataset:
Clinical trial NCT03107325: Biokinetics Study for F-18 FDG in Pediatric Molecular Imaging
Official title: Biokinetics Study for F-18 FDG for Dose Reduction in Pediatric Molecular Imaging
Sponsor: Boston Children's Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: No subjects who met the study criteria agreed to participate in two years prior to the COVID-19 crisis.
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-02-01
Primary completion date: 2020-10-01
Completion date: 2020-10-01
Plan to share individual participant data: YES
IPD sharing description: Anonymized patient data, with all protected patient information removed, will be shared with collaborators at Johns Hopkins University and the University of Florida. In particular, anonymized nuclear medicine image data will be shared for analysis.
Clinical trial NCT05263505: Baricitinib for the Treatment of Ocular Mucous Membrane Pemphigoid
Official title: Baricitinib for the Treatment of Ocular Mucous Membrane Pemphigoid
Sponsor: Washington University School of Medicine (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Sponsor
Enrollment: 2.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-02-21
Primary completion date: 2023-09-11
Completion date: 2023-09-11
Plan to share individual participant data: UNDECIDED
Clinical trial NCT01657604: TKI and Interferon Alpha Evaluation Initiated by the German Chronic Myeloid Leukemia Study Group - the TIGER Study
Official title: Treatment Optimization of Newly Diagnosed Ph/BCR-ABL Positive Patients With Chronic Myeloid Leukemia (CML) in Chronic Phase With Nilotinib vs. Nilotinib Plus Interferon Alpha Induction and Nilotinib or Interferon Alpha Maintenance Therapy
Acronym: TIGER
Sponsor: University of Jena (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 717.0 (ACTUAL)
Number of arms: 2.0
Start date: 2012-08-24
Primary completion date: 2022-05-31
Completion date: 2022-05-31
Clinical trial NCT03094169: AVID100 in Advanced Epithelial Carcinomas
Official title: Phase 1a/2a Dose Escalation Trial to Determine Safety, Tolerance, MTD, and Preliminary Antineoplastic Activity of AVID100, in Patients With Advanced or Metastatic Solid Tumors of Epithelial Origin
Sponsor: Formation Biologics (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: lack of efficacy
Enrollment: 49.0 (ACTUAL)
Number of arms: 4.0
Start date: 2017-02-01
Primary completion date: 2020-11-28
Completion date: 2021-01-30
Plan to share individual participant data: NO
Clinical trial NCT03428945: Hydroxychloroquine in Individuals At-risk for Type 1 Diabetes Mellitus
Official title: Hydroxychloroquine for Prevention of Abnormal Glucose Tolerance and Diabetes in Individuals At-risk for Type 1 Diabetes Mellitus (T1D)
Acronym: TN-22
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: This trial has undergone a prespecified interim analysis which determined that this treatment provides no statistically significant delay in the onset of abnormal glucose tolerance or Type 1 Diabetes.
Enrollment: 273.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-08-15
Primary completion date: 2022-10-27
Completion date: 2022-10-31
Limitations and caveats: Interim analysis completed prompted the DSMB's decision to terminate the protocol early limiting the originally planned follow up period for participants.
Clinical trial NCT03827200: A Study Evaluating the Utility of Ambrisentan in Lowering Portal Pressure in Patients With Liver Cirrhosis
Official title: A Phase II, Single-arm, Open-label Study to Characterise the Effect on Portal Pressure, the Effect on Renal Function and the Pharmacokinetic Profile of N-003 in Patients With Decompensated Cirrhosis
Sponsor: Noorik Biopharmaceuticals AG (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Lack of recruitment, result of COVID-19 pandemic
Enrollment: 19.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-04-11
Primary completion date: 2020-12-29
Completion date: 2021-01-21
Clinical trial NCT03843125: A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE)
Official title: A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Acronym: SLE-BRAVE-X
Sponsor: Eli Lilly and Company (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Study terminated due to insufficient evidence to support a positive benefit: risk profile. Safety findings were consistent with previously published OLUMIANT data
Enrollment: 1147.0 (ACTUAL)
Number of arms: 4.0
Start date: 2019-09-09
Primary completion date: 2022-04-01
Completion date: 2022-04-01
Baseline population: All randomized participants.
Limitations and caveats: This study was terminated due to insufficient evidence to support a positive benefit: risk profile. Safety findings were consistent with previously published OLUMIANT data.
Plan to share individual participant data: YES
IPD sharing description: Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
IPD time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
IPD access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Clinical trial NCT04840615: Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma
Official title: Phase I Study of Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma
Sponsor: National Institutes of Health Clinical Center (CC) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Study was closed early due to slow accrual.
Enrollment: 2.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-06-11
Primary completion date: 2021-12-06
Completion date: 2022-01-12
Plan to share individual participant data: YES
IPD sharing description: All individual participant data (IPD) recorded in the medical record will be shared with intramural investigators upon request.
IPD time frame: Clinical data in Biomedical Translational Research Information System (BTRIS) will be shared throughout the course of the study and indefinitely with the permission of the investigator.
IPD access criteria: Clinical individual participant data (IPD) will be shared through the Biomedical Translational Research Information System (BTRIS) database for open-ended analysis. All BTRIS subscribers, generally limited to the National Institutes of Health (NIH) Clinical Center, may request data.
Clinical trial NCT02476409: Tolvaptan For Worsening Outpatient Heart Failure: Role of Copeptin In Identifying Responders
Official title: Tolvaptan Treatment to Reverse Worsening Outpatient Heart Failure: Possible Role of Copeptin In Identifying Responders (TROUPER)
Acronym: TROUPER
Sponsor: University of North Carolina, Chapel Hill (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 40.0 (ACTUAL)
Number of arms: 2.0
Start date: 2015-07-31
Primary completion date: 2021-05-13
Completion date: 2021-05-13
Plan to share individual participant data: NO
Clinical trial NCT03266081: Bupivacaine Epiphora Trial
Official title: Improving Epiphora & Ptosis With Bupivacaine
Sponsor: McMaster University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: No patients
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2015-04-30
Primary completion date: 2022-08-23
Completion date: 2022-08-23
Plan to share individual participant data: NO
Clinical trial NCT02959944: Ibrutinib in Combination With Corticosteroids vs Placebo in Combination With Corticosteroids in Participants With New Onset Chronic Graft Versus Host Disease (cGVHD)
Official title: A Randomized, Double-Blind Phase 3 Study of Ibrutinib in Combination With Corticosteroids Versus Placebo in Combination With Corticosteroids in Subjects With New Onset Chronic Graft Versus Host Disease (cGVHD)
Acronym: iNTEGRATE
Sponsor: Pharmacyclics LLC. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 193.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-05-11
Primary completion date: 2020-03-27
Completion date: 2021-07-12
Plan to share individual participant data: YES
IPD sharing description: Requests for access to individual participant data from clinical studies conducted by Pharmacyclics LLC, an AbbVie Company, can be submitted through Yale Open Data Access (YODA) Project site at the following link.
Clinical trial NCT05111002: Lefamulin for M. Genitalium Treatment Failures
Official title: Lefamulin for Mycoplasma Genitalium Treatment Failures in the US
Sponsor: University of Washington (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: At Sponsor Request
Enrollment: 12.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-04-22
Primary completion date: 2023-11-30
Completion date: 2023-11-30
Limitations and caveats: This trial was stopped early due to cessation of operations by the antibiotic manufacturer and expiration of study drug. The number of study participants was less than designed and the small number of people resulted in unstable efficacy estimates and wide 95% confidence intervals.
Plan to share individual participant data: NO
IPD sharing description: Not federally funded. Currently no IPD sharing plan.
Clinical trial NCT06124144: Safety and Drug Absorption of Orally Administered Oleylphosphocholine (OlPC) in Healthy Adults
Official title: Safety and Pharmacokinetics of Oleylphosphocholine (OlPC), Administered Orally in Healthy Adults: A Phase 1, Single Center, Open-label, Staggered, Dose-escalation Trial
Sponsor: University Hospital Tuebingen (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: The risk-benefit ratio changed
Enrollment: 13.0 (ACTUAL)
Number of arms: 1.0
Start date: 2023-06-21
Primary completion date: 2024-02-27
Completion date: 2024-02-27
Clinical trial NCT01970410: MAIN STUDY: SWITCH SUB-STUDY: SWITCH-JCV
Official title: MAIN STUDY: Switching Relapsing Multiple Sclerosis Patients Treated With Natalizumab at Risk for Progressive Multifocal Leukoencephalopathy to Teriflunomide: Is This Safe and Effective? SUB-STUDY: Analysis of JCV Antibody Index in MS Patients Treated With Teriflunomide
Sponsor: Providence Health & Services (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 55.0 (ACTUAL)
Number of arms: 1.0
Start date: 2013-10-31
Primary completion date: 2021-04-30
Completion date: 2022-02-14
Baseline population: Main study participants.
Clinical trial NCT03579160: Efficacy and Safety of 0.25% Timolol Gel in Enhancing Full Thickness Skin Grafts Healing and Cosmetic Outcomes
Official title: Efficacy and Safety of 0.25% Timolol Gel in Enhancing Full Thickness Skin Grafts Healing and Cosmetic Outcomes: A Randomized, Controlled Trial
Acronym: FTSG
Sponsor: Brigham and Women's Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: TERMINATED 
Why stopped: Due to the insufficient accrual rate and strategic reasons to focus our efforts on higher impact research projects.
Enrollment: 10.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-01-02
Primary completion date: 2022-01-10
Completion date: 2022-01-10
Plan to share individual participant data: UNDECIDED
Clinical trial NCT04128176: Efficacy and Safety of Rituximab Combined With Omalizumab in Patients With Bullous Pemphigoid
Official title: An Open-Label Study to Evaluate the Efficacy and Safety of Rituximab Combined With Omalizumab in Patients With Bullous Pemphigoid
Sponsor: University of California, Davis (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: PI did not pursue this study; this study was not IRB-approved and never started.
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-03-31
Primary completion date: 2023-05-25
Completion date: 2023-11-25
Plan to share individual participant data: NO
Clinical trial NCT03189719: First-line Esophageal Carcinoma Study With Pembrolizumab Plus Chemo vs. Chemo (MK-3475-590/KEYNOTE-590)
Official title: A Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial of Pembrolizumab (MK-3475) in Combination With Cisplatin and 5-Fluorouracil Versus Placebo in Combination With Cisplatin and 5-Fluorouracil as First-Line Treatment in Subjects With Advanced/Metastatic Esophageal Carcinoma (KEYNOTE-590)
Sponsor: Merck Sharp & Dohme LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 749.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-07-25
Primary completion date: 2020-07-02
Completion date: 2023-07-10
Plan to share individual participant data: YES
IPD sharing description: http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Clinical trial NCT03451825: Phase I/II Study of Avelumab in Pediatric Cancer Participants
Official title: Open-label, Phase I/II Study to Evaluate Pharmacokinetics, Pharmacodynamics, Safety, and Anticancer Activity of Avelumab in Pediatric Subjects From Birth to Less Than 18 Years of Age With Refractory or Relapsed Solid Tumors and Lymphoma
Sponsor: EMD Serono (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Based on the limited activity observed with avelumab monotherapy in the pediatric population, the Phase II study part was cancelled.
Enrollment: 21.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-03-07
Primary completion date: 2021-07-27
Completion date: 2021-07-27
Baseline population: Full analysis set included all participants who had received any dose of avelumab.
Limitations and caveats: The study was planned to be conducted in 2 parts: the dose-finding part (Phase I) and the tumor-specified expansion part (Phase II). However, Phase II was cancelled due to limited clinical benefit of PD-L1 monotherapy in pediatric participants.
Clinical trial NCT03487276: Efficacy and Safety Study of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)
Official title: A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Study to Determine Efficacy and Safety of IFX-1 in Subjects With Moderate to Severe Hidradenitis Suppurativa
Acronym: SHINE
Sponsor: InflaRx GmbH (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 179.0 (ACTUAL)
Number of arms: 5.0
Start date: 2018-02-26
Primary completion date: 2019-05-27
Completion date: 2020-01-27
Baseline population: Baseline analysis performed for safety analysis set (SAS)
Plan to share individual participant data: NO
Clinical trial NCT05152849: Efficacy, Safety, Tolerability of AXA1125 in Fatigue After COVID-19 Infection
Official title: A Randomized, Double-Blind, Placebo-Controlled Pilot Study to Evaluate the Efficacy, Safety, and Tolerability of AXA1125 in Subjects With Fatigue-Predominant Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection
Sponsor: Axcella Health, Inc (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 41.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-12-15
Primary completion date: 2022-06-21
Completion date: 2022-06-29
Clinical trial NCT04049097: Arimoclomol in Sporadic Inclusion Body Myositis - Open Label Extension Trial
Official title: An Open-label, Non-randomized Trial to Investigate the Efficacy and Safety of Early Versus Delayed Start of Arimoclomol in Patients With Sporadic Inclusion Body Myositis Who Have Completed the IBM4809 Trial
Sponsor: ZevraDenmark (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: As a consequence of the results of IBM4809 which did not meet any of its efficacy endpoints. The planned duration of open-label treatment was 40 months. After termination, the actual mean duration of treatment was approx. 28 weeks.
Enrollment: 121.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-05-20
Primary completion date: 2021-11-15
Completion date: 2021-11-15
Baseline population: Safety population: All patients who received at least 1 dose or partial dose of arimoclomol in IBM-OLE.
Clinical trial NCT03396471: Study of Pembrolizumab and Concurrent Radiation in Patients With Previously Treated Carcinoma of Unknown Primary
Official title: Single-arm Phase 2 Study to Examine Pembrolizumab and Concurrent Radiation to Induce an Abscopal Effect in Patients With Previously Treated Carcinoma of Unknown Primary (CUP16-268)
Sponsor: Hoosier Cancer Research Network (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Study failed to meet its interim analysis endpoint
Enrollment: 14.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-02-01
Primary completion date: 2021-08-12
Completion date: 2023-03-02
Plan to share individual participant data: UNDECIDED
Clinical trial NCT03510884: An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia
Official title: A Randomized, Double-Blind, Placebo-Controlled Study Followed by an Open Label Treatment Period to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia
Sponsor: Sanofi (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 153.0 (ACTUAL)
Number of arms: 4.0
Start date: 2018-05-31
Primary completion date: 2021-01-14
Completion date: 2022-08-05
Baseline population: Analysis was performed on all randomized participants.
Plan to share individual participant data: NO
Clinical trial NCT04626297: A Study of Lebrikizumab (LY3650150) on Vaccine Response in Adults With Atopic Dermatitis (ADopt-VA)
Official title: A Phase 3, 16-week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-to-Severe Atopic Dermatitis
Sponsor: Eli Lilly and Company (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 254.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-11-17
Primary completion date: 2022-08-03
Completion date: 2022-09-30
Baseline population: All randomized participants.
Plan to share individual participant data: YES
IPD sharing description: Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
IPD time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.
IPD access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Clinical trial NCT03913130: Extension Study to Study PQ-110-001 (NCT03140969)
Official title: An Open-Label, Extension Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of QR-110 in Subjects With Leber's Congenital Amaurosis (LCA) Due to the c.2991+1655A>G Mutation (p.Cys998X) in the CEP290 Gene
Acronym: INSIGHT
Sponsor: Laboratoires Thea (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Terminated \[Study prematurely terminated due to sponsor decision for reasons unrelated to safety\]
Enrollment: 9.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-05-13
Primary completion date: 2022-10-03
Completion date: 2022-10-03
Plan to share individual participant data: NO
Clinical trial NCT02076672: Investigation of the Anti-Cancer Activity of Artichoke Extract in an Asbestos-Exposed Population
Official title: Investigation of the Anti-Cancer Activity of Artichoke Extract in an Asbestos-Exposed Population (The ABOCA Phase II Trial)
Acronym: ABOCA1
Sponsor: Ontario Clinical Oncology Group (OCOG) (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 3.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-11-05
Primary completion date: 2020-04-28
Completion date: 2020-04-28
Clinical trial NCT02426086: Study to Evaluate Activity of 2 Dose Levels of Imetelstat in Participants With Intermediate-2 or High-Risk Myelofibrosis (MF) Previously Treated With Janus Kinase (JAK) Inhibitor
Official title: A Randomized, Single-Blind, Multicenter Phase 2 Study to Evaluate the Activity of 2 Dose Levels of Imetelstat in Subjects With Intermediate-2 or High-Risk Myelofibrosis (MF) Relapsed/Refractory to Janus Kinase (JAK) Inhibitor
Sponsor: Geron Corporation (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 107.0 (ACTUAL)
Number of arms: 2.0
Start date: 2015-08-28
Primary completion date: 2018-04-26
Completion date: 2020-02-07
Baseline population: Intent-to-Treat (ITT) analysis set included all participants randomized into the study and classified according to their assigned treatment group.
Clinical trial NCT03454893: Open Label, Study Of Efficacy and Safety Of AVR-RD-01 for Treatment-Naive Subjects With Classic Fabry Disease
Official title: An Open-Label, Multinational Study Of The Efficacy And Safety of Ex Vivo, Lentiviral Vector-Mediated Gene Therapy AVR-RD-01 For Treatment-Naive Subjects With Classic Fabry Disease
Sponsor: AVROBIO (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: AVROBIO has deprioritized its Fabry disease program
Enrollment: 15.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-02-21
Primary completion date: 2022-03-14
Completion date: 2022-03-14
Baseline population: Safety population consists of all enrolled subjects who received any preparatory medication.
Limitations and caveats: SF-36 data at W24 was inadvertently not collected due to omission in the Protocol Schedule of Assessments.~Invasive sampling, such as bone marrow aspirate, was only provided by one subject at Week 48.~Central laboratory only reported albumin levels in urine and not urine total protein data.
Plan to share individual participant data: NO
Clinical trial NCT02990091: Derivatives of Omega-3 HUFA as Biomarkers of Traumatic Brain Injury
Official title: Traumatic Brain Injury Recovery With n-3 Highly Unsaturated Fatty Acids (HUFAs): A Biomarker-driven Approach
Sponsor: University of Pennsylvania (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Unable to recruit participants
Enrollment: 0.0 (ACTUAL)
Number of arms: 4.0
Start date: 2017-01-31
Primary completion date: 2023-01-31
Completion date: 2023-12-31
Plan to share individual participant data: NO
Clinical trial NCT02853578: Busonid® (Budesonide 200 mcg and 400 mcg) to Treat Asthma Not Controlled or Partially Controlled
Official title: National Clinical Study, Multicentric, Single Arm to Evaluate the Efficacy and Safety of Busonid® (Budesonide 200 mcg and 400 mcg) to Treat Asthma Not Controlled or Partially Controlled
Acronym: Laennec
Sponsor: Ache Laboratorios Farmaceuticos S.A. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: SUSPENDED 
Why stopped: The viability of the study is being analyzed
Enrollment: 80.0 (ESTIMATED)
Number of arms: 1.0
Start date: 2019-12-31
Primary completion date: 2020-10-31
Completion date: 2020-12-31
Clinical trial NCT01062399: Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Official title: Phase I/II Trial of Concurrent RAD001 (Everolimus) With Temozolomide/Radiation Followed by Adjuvant RAD001/Temozolomide in Newly Diagnosed Glioblastoma
Acronym: RTOG 0913
Sponsor: Radiation Therapy Oncology Group (NETWORK)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: COMPLETED 
Enrollment: 279.0 (ACTUAL)
Number of arms: 5.0
Start date: 2010-12-31
Primary completion date: 2016-06-30
Completion date: 2022-05-20
Baseline population: Eligible randomized patients